Therefore, treatment with anti-IL-23 antibodies, along with increasing the number and function of Tregs, may offer therapeutic potential for IBD patients resistant to IL-23 inhibitors alone and for inducing long-term remission by restoring gut immune tolerance. The gene discussed is IL23A; the disease is inflammatory bowel disease.